Yino Pharma Limited

Yino Pharma Limited, established in 2009, is a manufacturer of prophylactic biological products and specialized reagents notable for its integrated 'intestine to API' production model at a single site, implementing best practices under Annex 2 of the EU GMP Guidelines and FDA Guidance for Industry to ensure full traceability. Offering own-brand production to customers across North and South America, Europe, Asia, the Middle East, and Africa, the company competes on international approvals, experienced R&D staff, production capacity, and quality service, while accommodating buyers' specifications.